MEGAN NUSZ: Open Payments
NPI 1790458826 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$842 in 34 payments from 21 companies in 2025. Trend: 2023 $50 · 2024 $0 · 2025 $842
Food & beverage: $643Education: $200
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $250 |
| Janssen Biotech, Inc. | 3 | $74 |
| Merck Sharp & Dohme LLC | 4 | $69 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Genentech USA, Inc. | 2 | $48 |
| Iovance Biotherapeutics, Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| TerSera Therapeutics LLC | 1 | $31 |
| Astellas Pharma US Inc | 1 | $30 |
| SERVIER PHARMACEUTICALS LLC | 1 | $23 |
Products named: VENCLEXTA, KEYTRUDA, Amtagvi, RYBREVANT, LYNOZYFIC, CARVYKTI, Zoladex, Vyloy.
Industry payments across NE — which companies pay providers there.
